Stockscreener 앱 받기
6.52
2.83%
-0.19
시간 외 거래:
6.57
0.05
+0.77%
전일 마감가:
$6.71
열려 있는:
$6.59
하루 거래량:
5.10M
Relative Volume:
1.01
시가총액:
$1.69B
수익:
$6.28B
순이익/손실:
$700.00M
주가수익비율:
2.4218
EPS:
2.6922
순현금흐름:
$537.00M
1주 성능:
-2.10%
1개월 성능:
-40.78%
6개월 성능:
-32.01%
1년 성능:
-61.47%
1일 변동 폭
$6.49
$6.70
1주일 범위
$6.18
$6.925
52주 변동 폭
$6.18
$17.23
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.52 | 1.74B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
906.86 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
215.89 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
L’Association canadienne pour l’équité en santé des femmes et ses partenaires réclament un investissement audacieux dans la santé des femmes afin de combler définitivement les inégalités - GlobeNewswire Inc.
Aviance Capital Partners LLC Takes $599,000 Position in Organon & Co. $OGN - MarketBeat
Institutional Investors May Adopt Severe Steps After Organon & Co.'s (NYSE:OGN) Latest 26% Drop Adds to a Year Losses - 富途牛牛
Organon & Co. $OGN Holdings Cut by Fisher Funds Management LTD - MarketBeat
Organon & Co. Stock Plummets to New 52-Week Low of $6.18 - Markets Mojo
Co. (7XP) stock survive global slowdownQuarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN) - MSN
Organon & Co. (OGN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
KLCM Advisors Inc. Decreases Stake in Organon & Co. $OGN - MarketBeat
Crisis at Organon: Leadership Ousted Amid Sales Scandal - AD HOC NEWS
Tangible book value per share of Organon & Co. – BMV:OGN - TradingView
OGN 8-K/A discloses interim Executive Chair compensation terms - Stock Titan
The Vanguard Group files 13G/A for Organon with 13.82% stake - Stock Titan
Organon & Co. Common Stock (NY: OGN - FinancialContent
Organon stock plunges as CEO resigns amid Nexplanon sales probe - MSN
The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media
Organon & Co. $OGN Shares Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Co. (7XP) stock in 20252025 Sector Review & Safe Entry Point Alerts - newser.com
Organon & Co. (OGN) Stock forecasts - Yahoo! Finance UK
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon (OGN) Price Target Decreased by 15.36% to 11.05 - Nasdaq
Organon & Co. (NYSE:OGN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat
Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights
Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st
Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat
D.A. Davidson & CO. Sells 50,248 Shares of Organon & Co. $OGN - MarketBeat
Why Organon (OGN) Stock Is Down Today - Yahoo Finance
Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade
Organon hit hard over ousted CEO scandal - The Pharma Letter
The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 52-Week Low After Analyst Downgrade - MarketBeat
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - MarketScreener
Organon & Co. (NYSE:OGN) Downgraded by Piper Sandler to Underweight - MarketBeat
Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛
Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize
Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia
Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ
Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada
Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - MSN
Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma
Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize
Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ
Organon CEO exits after internal probe over ‘channel stuffing’ to boost sales - Endpoints News
Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance
Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.88%
0.78%
자본화:
|
볼륨(24시간):